Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir

The two direct-acting antiviral (2D) regimen of ombitasvir and paritaprevir (administered with low-dose ritonavir) is being developed for treatment of genotype subtype 1b and genotypes 2 and 4 chronic hepatitis C virus (HCV) infection. Drug-drug interactions were evaluated in healthy volunteers to d...

Descripción completa

Detalles Bibliográficos
Autores principales: Badri, Prajakta S., Dutta, Sandeep, Wang, Haoyu, Podsadecki, Thomas J., Polepally, Akshanth R., Khatri, Amit, Zha, Jiuhong, Chiu, Yi-Lin, Awni, Walid M., Menon, Rajeev M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2015
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4704150/
https://www.ncbi.nlm.nih.gov/pubmed/26459906
http://dx.doi.org/10.1128/AAC.01778-15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4704150/
https://www.ncbi.nlm.nih.gov/pubmed/26459906
http://dx.doi.org/10.1128/AAC.01778-15

Ejemplares similares